In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22

AAPS Journal

Volumn 18, Issue 2, 2016, Pages 455-464

  Diao, Xingxing ^a   Scheidweiler, Karl B ^a   Wohlfarth, Ariane ^b,c   Pang, Shaokun ^d   Kronstrand, Robert ^b,c   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d MDS SCIEX   (Canada)

Author keywords

FDU PB 22; FUB PB 22; hepatocyte metabolism; high resolution mass spectrometry; synthetic cannabinoid

Indexed keywords

BETA GLUCURONIDASE; CANNABINOID; DRUG METABOLITE; FLUOROBENZYLINDOLE 3 CARBOXYLIC ACID; NAPHTHALEN 1 YL 1 [(4 FLUOROPHENYL)METHYL] 1H INDOLE 3 CARBOXYLATE; QUINOLIN 8 YL 1 [(4 FLUOROPHENYL)METHYL] 1H INDOLE 3 CARBOXYLATE; UNCLASSIFIED DRUG; PLANT MEDICINAL PRODUCT;

ARTICLE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MASS SPECTROMETRY; URINE; CHEMISTRY; DRUG EFFECTS; METABOLISM;

CANNABINOIDS; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; PLANT PREPARATIONS;

EID: 84959463853     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-016-9867-4     Document Type: Article

References (39)

1. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147 Suppl 1:S163–71.
2. Huffman JW, Dai D, Martin BR, Compton DR. Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett. 1994;4(4):563–6.
3. Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, et al. First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem. 2013;59(11):1638–48.
4. Hermanns-Clausen M, Kneisel S, Szabo B, Auwarter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108(3):534–44.
5. Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):234–43.
6. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012;31(10):1006–11.
7. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med. 2012;30(7):1320 e5–7.
8. Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA. Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem. 2014;406(6):1763–80.
9. Uchiyama N, Asakawa K, Kikura-Hanajiri R, Tsutsumi T, Hakamatsuka T. A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide] identified in illegal products. Forensic Toxicol. 2015;33(2):367–73.
10. European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in Europe. 2015 [cited 2015 April 12]; Available from: http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf.
11. Uchiyama N, Shimokawa Y, Kawamura M, Kikura-Hanajiri R, Hakamatsuka T. Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol. 2014;32(2):266–81.
12. Uchiyama N, Shimokawa Y, Kikura-Hanajiri R, Demizu Y, Goda Y, Hakamatsuka T. A synthetic cannabinoid FDU-NNEI, two 2H-indazole isomers of synthetic cannabinoids AB-CHMINACA and NNEI indazole analog (MN-18), a phenethylamine derivative N-OH-EDMA, and a cathinone derivative dimethoxy-alpha-PHP, newly identified in illegal products. Forensic Toxicol. 2015;33(2):244–59.
13. Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Baranovsky A, Shafran Y. Synthetic cannabinoids as designer drugs: new representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data. Forensic Sci Int. 2014;244:263–75.
14. Roussel O, Cralin MG, Bouvot X, Tensorer L. The emergence of synthetic cannabinoids in Mayotte. Toxicol Anal Clin. 2015;27:18–22.
15. Drugs-Forum. [cited 2015 May 18]; Available from: https://drugs-forum.com/forum/showthread.php?t=231374.
16. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012;40(11):2174–84.
17. Sobolevsky T, Prasolov I, Rodchenkov G. Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal. 2012;4(10):745–53.
18. Scheidweiler KB, Jarvis MJ, Huestis MA. Nontargeted SWATH acquisition for identifying 47 synthetic cannabinoid metabolites in human urine by liquid chromatography-high-resolution tandem mass spectrometry. Anal Bioanal Chem. 2015;407(3):883–97.
19. Castaneto MS, Wohlfarth A, Pang SK, Zhu MS, Scheidweiler KB, Kronstrand R, et al. Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry. Forensic Toxicol. 2015;33(2):295–310.
20. Diao X, Pang X, Xie C, Guo Z, Zhong D, Chen X. Bioactivation of 3-n-butylphthalide via sulfation of its major metabolite 3-hydroxy-NBP: mediated mainly by sulfotransferase 1A1. Drug Metab Dispos. 2014;42(4):774–81.
21. Soars MG, McGinnity DF, Grime K, Riley RJ. The pivotal role of hepatocytes in drug discovery. Chem Biol Interact. 2007;168(1):2–15.
22. Wohlfarth A, Castaneto MS, Zhu M, Pang S, Scheidweiler KB, Kronstrand R, et al. Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J. 2015;17(3):660–77.
23. Wohlfarth A, Scheidweiler KB, Pang S, Zhu M, Castaneto M, Kronstrand R, et al. Metabolic characterization of AH-7921, a synthetic opioid designer drug: in vitro metabolic stability assessment and metabolite identification, evaluation of in silico prediction, and in vivo confirmation. Drug Test Anal. 2015. doi:10.1002/dta.1856.
24. Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, et al. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep. 2006;58(4):453–72.
25. McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe JO, Belcastro JV, et al. An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. Assay Drug Dev Technol. 2008;6(1):121–9.
26. Diao XX, Zhong K, Li XL, Zhong DF, Chen XY. Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier. Acta Pharmacol Sin. 2015;36(12):1520–7.
27. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, et al. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res. 1997;14(2):152–5.
28. Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K. Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test Anal. 2015;7(7):565–76.
29. Holm NB, Pedersen AJ, Dalsgaard PW, Linnet K. Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test Anal. 2015;7(3):199–206.
30. Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA. High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid THJ-018 and its 5-fluoro analog THJ-2201 after incubation in human hepatocytes. Clin Chem. 2016;62(1):157–69.
31. Michael JP. Quinoline, quinazoline and acridone alkaloids. Nat Prod Rep. 1999;16(6):697–709.
32. Li XD, Xia SQ, Lv Y, He P, Han J, Wu MC. Conjugation metabolism of acetaminophen and bilirubin in extrahepatic tissues of rats. Life Sci. 2004;74(10):1307–15.
33. Gao C, Zhang H, Guo Z, You T, Chen X, Zhong D. Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab Dispos. 2012;40(10):2009–20.
34. Xie C, Zhou J, Guo Z, Diao X, Gao Z, Zhong D, et al. Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013;168(7):1687–706.
35. Gao R, Li L, Xie C, Diao X, Zhong D, Chen X. Metabolism and pharmacokinetics of morinidazole in humans: identification of diastereoisomeric morpholine N+-glucuronides catalyzed by UDP glucuronosyltransferase 1A9. Drug Metab Dispos. 2012;40(3):556–67.
36. Kitamura T, Suzuki M, Nishimatsu H, Kurosaki T, Enomoto Y, Fukuhara H, et al. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer. Aktuelle Urol. 2010;41 Suppl 1:S34–40.
37. Li AP, Gorycki PD, Hengstler JG, Kedderis GL, Koebe HG, Rahmani R, et al. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chem Biol Interact. 1999;121(1):117–23.
38. Ellefsen K, Wohlfarth A, Swortwood M, Diao X, Concheiro M, Huestis M. 4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicol. 2016;34(1):61–75.
39. Swortwood MJ, Carlier J, Ellefsen KN, Wohlfarth A, Diao X, Concheiro-Guisan M, et al. In vitro, in vivo and in silico metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis. 2016;8(1):65–82.